Literature DB >> 15012906

Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease.

Josef Matousek1, Josef Soucek, Tomás Slavík, Milan Tománek, J Eugene Lee, Ronald T Raines.   

Abstract

Onconase (ONC) and bovine seminal ribonuclease (BS-RNase) are homologs of bovine pancreatic ribonuclease (RNase A). Unlike RNase A, ONC and BS-RNase can evade the cytosolic ribonuclease inhibitor protein and are potent cytotoxins. Here, the endogenous cytotoxic activities of ONC and BS-RNase are compared in a wide variety of assays. Injections of ONC into one or both testes of mice and rats evokes a stronger aspermatogenic activity than does the injection of BS-RNase. Epididymides exposed to ONC lose mass and all sperm. Testicular tissue is gradually colonized by immunite and fibrocytic cells. Yet, Leydig cells are always present and functional in the ligamented parts of testicles injected with ONC or BS-RNase. ONC is likewise more toxic to mouse embryos than is BS-RNase, both in vitro and in vivo. The antiproliferative effect of ONC on human tumor cell line ML-2 and lymphocytes in a mixed lymphocyte culture is also more pronounced than is that of BS-RNase. The number of granulocyte-macrophage colony-forming units is repressed almost completely by ONC, whereas a five-fold higher dose of BS-RNase does not cause substantial inhibition. In mice, ONC is less immunogenic than BS-RNase but more immunogenic than RNase A. Together, these data indicate that ONC is a pluripotent cytotoxin, and serves as the benchmark with which to gauge the cytotoxicity of other ribonucleases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15012906     DOI: 10.1016/j.cca.2003.10.005

Source DB:  PubMed          Journal:  Comp Biochem Physiol C Toxicol Pharmacol        ISSN: 1532-0456            Impact factor:   3.228


  15 in total

1.  Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity.

Authors:  Thomas J Rutkoski; John A Kink; Laura E Strong; Ronald T Raines
Journal:  Cancer Biol Ther       Date:  2011-08-01       Impact factor: 4.742

2.  Binase does not induce polyclonal T-cell response.

Authors:  P V Zelenikhin; G V Cherepnev; F Kern; O N Ilinskaia
Journal:  Dokl Biol Sci       Date:  2006 Mar-Apr

3.  Oxidative folding and N-terminal cyclization of onconase.

Authors:  Ervin Welker; Laura Hathaway; Guoqiang Xu; Mahesh Narayan; Lovy Pradeep; Hang-Cheol Shin; Harold A Scheraga
Journal:  Biochemistry       Date:  2007-04-18       Impact factor: 3.162

4.  Rational design and evaluation of mammalian ribonuclease cytotoxins.

Authors:  Jo E Lomax; Chelcie H Eller; Ronald T Raines
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

5.  Polyarginine as a multifunctional fusion tag.

Authors:  Stephen M Fuchs; Ronald T Raines
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

Review 6.  The RNase a superfamily: generation of diversity and innate host defense.

Authors:  Kimberly D Dyer; Helene F Rosenberg
Journal:  Mol Divers       Date:  2006-11       Impact factor: 2.943

Review 7.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

Authors:  Thomas J Rutkoski; Ronald T Raines
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

Review 8.  Ribonucleases as novel chemotherapeutics : the ranpirnase example.

Authors:  J Eugene Lee; Ronald T Raines
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

9.  Molecular docking and dynamics simulations of A.niger RNase from Aspergillus niger ATCC26550: for potential prevention of human cancer.

Authors:  Gundampati Ravi Kumar; Rajasekhar Chikati; Santhi Latha Pandrangi; Manoj Kandapal; Kirti Sonkar; Neeraj Gupta; Chaitanya Mulakayala; Medicherla V Jagannadham; Chitta Suresh Kumar; Sunita Saxena; Mira Debnath Das
Journal:  J Mol Model       Date:  2012-09-16       Impact factor: 1.810

Review 10.  Ribonucleases as potential modalities in anticancer therapy.

Authors:  Wojciech Ardelt; Barbara Ardelt; Zbigniew Darzynkiewicz
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.